意大利BRCA突变上皮性卵巢癌患者的特征与结局:MITO 21回顾性多中心研究
一线化疗后中位无进展生存期为29个月,5年生存率为72.5%(CI 60.2-80.8%),手术无残留病灶(R=0)是唯一预测更长总生存的因素。
要点
- BRCA1突变占72%,BRCA2突变占27.5%,中位诊断年龄52岁。
- 一线化疗后中位无进展生存期29个月,5年生存率72.5%。
- 手术无残留病灶(R=0)是唯一预测更长总生存的因素。
核心结论
- 这是意大利最大的BRCA突变上皮性卵巢癌队列,手术无残留病灶是唯一预测更长总生存的因素。
- 后续发生乳腺癌的卵巢癌患者为长期生存者。
主要发现
- 最常见诊断为高级别浆液性FIGO III或IV期上皮性卵巢癌,几乎所有患者一线接受铂类双药化疗。
- 一线化疗后中位无进展生存期为29个月,5年生存率为72.5%(CI 60.2-80.8%)。
关键数值与推荐
- BRCA1 founder突变c.5266dupC是最常记录的突变。
临床怎么用
- 对于BRCA突变上皮性卵巢癌患者,应致力于手术达到无残留病灶以改善总生存。
- BRCA突变卵巢癌患者需关注后续乳腺癌发生风险,尤其是长期生存者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Around 15% of epithelial ovarian cancer (EOC) patients (pts) harbor a germline BRCA1 or 2 mutation, showing different features than BRCA wild-type pts. The clinical and pathological features of an Italian BRCA mutated EOC cohort were described. METHODS: We retrospectively analyzed clinical, pathological and mutational data from a cohort of Italian BRCA mutated EOC pts. treated in 15 MITO centers between 1995 and 2017. RESULTS: Three-hundred thirty-one pts. were recorded. Two-hundred forty (72%) and 91 (27.5%) pts. harbored a BRCA1 and BRCA2 mutation, respectively. Median age at diagnosis was 52 years. The most frequent diagnosis was a high grade serous FIGO III or IV EOC and platinum doublet in first-line was administered to almost all pts. Fifty-three % of them had no residual disease (R = 0) at surgery. Median progression-free-survival (mPFS) after first-line chemotherapy was 29 months. Expected percentage of pts. alive at 5 years was 72.5% (CI 60.2-80.8%) and R = 0 predicted a significantly longer overall survival (OS). Sixty-six pts. (19,9%) had both an EOC and a breast cancer (BC) diagnosis. The first diagnosis was BC in 81,8% of cases with a mean interval between the two diagnoses (IBTDs) of 132.4 months. Mutational data show that the founder mutation c.5266dupC in BRCA1 was the most frequently recorded. CONCLUSIONS: This is the largest Italian BRCA mutEOC cohort. The only predictor of longer OS was R = 0. EOC pts. that developed subsequently a BC are long-term survivors.
引用
- Artioli G, Giannone G, Valabrega G, et al. Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). Gynecol Oncol. 2021. PMID: 33888336. doi:10.1016/j.ygyno.2021.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。